600479 千金药业
已收盘 12-18 15:00:00
资讯
新帖
简况
千金药业(600479)披露子公司获得药品注册证书,12月12日股价下跌0.29%
证券之星 · 12-12
千金药业(600479)披露子公司获得药品注册证书,12月12日股价下跌0.29%
千金药业(600479.SH):盐酸鲁拉西酮片获得药品注册证书
智通财经 · 12-12
千金药业(600479.SH):盐酸鲁拉西酮片获得药品注册证书
千金药业(600479)披露标的资产过渡期损益情况,12月10日股价下跌0.29%
证券之星 · 12-10
千金药业(600479)披露标的资产过渡期损益情况,12月10日股价下跌0.29%
千金药业:2025年三季度披露财务报表未将收购部分股权的利润纳入归母净利润
证券日报 · 12-10
千金药业:2025年三季度披露财务报表未将收购部分股权的利润纳入归母净利润
每周股票复盘:千金药业(600479)取消监事会并修订章程
证券之星 · 11-23
每周股票复盘:千金药业(600479)取消监事会并修订章程
千金药业(600479)披露2025年第三季度业绩说明会召开情况,11月20日股价上涨0.47%
证券之星 · 11-20
千金药业(600479)披露2025年第三季度业绩说明会召开情况,11月20日股价上涨0.47%
每周股票复盘:千金药业(600479)拟取消监事会,注册资本变更至49221.0016万股
证券之星 · 11-16
每周股票复盘:千金药业(600479)拟取消监事会,注册资本变更至49221.0016万股
千金药业(600479)披露召开2025年第三季度业绩说明会,11月14日股价上涨0.91%
证券之星 · 11-14
千金药业(600479)披露召开2025年第三季度业绩说明会,11月14日股价上涨0.91%
千金药业(600479)披露拟取消监事会并修订公司章程,11月11日股价上涨1.11%
证券之星 · 11-11
千金药业(600479)披露拟取消监事会并修订公司章程,11月11日股价上涨1.11%
每周股票复盘:千金药业(600479)Q3净利增18.42%,股东户数降9.85%
证券之星 · 11-02
每周股票复盘:千金药业(600479)Q3净利增18.42%,股东户数降9.85%
图解千金药业三季报:第三季度单季净利润同比增长18.42%
证券之星 · 10-29
图解千金药业三季报:第三季度单季净利润同比增长18.42%
千金药业最新公告:子公司千金湘江药业获得富马酸伏诺拉生片与恩格列净片药品注册证书
证券之星 · 10-13
千金药业最新公告:子公司千金湘江药业获得富马酸伏诺拉生片与恩格列净片药品注册证书
每周股票复盘:千金药业(600479)收购两子公司股权
证券之星 · 09-28
每周股票复盘:千金药业(600479)收购两子公司股权
每周股票复盘:千金药业(600479)完成收购两子公司股权过户
证券之星 · 09-21
每周股票复盘:千金药业(600479)完成收购两子公司股权过户
千金药业(600479)披露发行股份及支付现金购买资产之标的资产过户完成公告,9月17日股价下跌1.1%
证券之星 · 09-17
千金药业(600479)披露发行股份及支付现金购买资产之标的资产过户完成公告,9月17日股价下跌1.1%
每周股票复盘:千金药业(600479)并购获证监会注册批复
证券之星 · 09-14
每周股票复盘:千金药业(600479)并购获证监会注册批复
千金药业(600479)披露收购报告书半年度持续督导公告,9月11日股价上涨1.45%
证券之星 · 09-11
千金药业(600479)披露收购报告书半年度持续督导公告,9月11日股价上涨1.45%
千金药业(600479)2025年中报简析:净利润同比增长8.5%,盈利能力上升
证券之星 · 08-31
千金药业(600479)2025年中报简析:净利润同比增长8.5%,盈利能力上升
图解千金药业中报:第二季度单季净利润同比增长4.26%
证券之星 · 08-29
图解千金药业中报:第二季度单季净利润同比增长4.26%
千金药业(600479)6月30日股东户数4.09万户,较上期减少4.16%
证券之星 · 08-29
千金药业(600479)6月30日股东户数4.09万户,较上期减少4.16%
暂无数据
公司概况
公司名称:
株洲千金药业股份有限公司
所属行业:
医药制造业
上市日期:
2004-03-12
主营业务:
株洲千金药业股份有限公司的主营业务是中成药、化学药、女性卫生用品的研发、生产和销售,以及药品的批发和零售业务。公司的主要产品是妇科千金片(胶囊)、补血益母丸(颗粒)、缬沙坦胶囊、马来酸依那普利片、盐酸地芬尼多片、水飞蓟宾葡甲胺片、苯磺酸氨氣地平片、非那雄胺片以及妇科专用棉巾系列等。公司连续十多年保持口服妇科炎症中成药市场第一品牌地位。“千金”是国家驰名商标。千金药业荣获“2025中国中药研发实力前50强”“2025大健康产业影响力品牌”等奖项。
发行价格:
23.05
{"stockData":{"symbol":"600479","market":"SH","secType":"STK","nameCN":"千金药业","latestPrice":10.45,"timestamp":1766041201000,"preClose":10.26,"halted":0,"volume":6109400,"delay":0,"changeRate":0.0185,"floatShares":419000000,"shares":492000000,"eps":0.508,"marketStatus":"已收盘","change":0.19,"latestTime":"12-18 15:00:00","open":10.27,"high":10.46,"low":10.25,"amount":63432900,"amplitude":0.0205,"askPrice":10.45,"askSize":224,"bidPrice":10.44,"bidSize":321,"shortable":0,"etf":0,"ttmEps":0.508,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766107800000},"marketStatusCode":5,"adr":0,"adjPreClose":10.26,"symbolType":"stock","openAndCloseTimeList":[[1766021400000,1766028600000],[1766034000000,1766041200000]],"highLimit":11.29,"lowLimit":9.23,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":492210016,"isCdr":false,"pbRate":2.06,"roa":"--","peRate":20.570866,"roe":"7.53%","epsLYR":0.5579,"committee":-0.597501,"marketValue":5144000000,"turnoverRate":0.0146,"status":0,"floatMarketCap":4373000000},"requestUrl":"/m/hq/s/600479/tweets","defaultTab":"tweets","newsList":[{"id":"2590025085","title":"千金药业(600479)披露子公司获得药品注册证书,12月12日股价下跌0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590025085","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590025085?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:27","pubTimestamp":1765549649,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘,千金药业报收于10.23元,较前一交易日下跌0.29%,最新总市值为50.35亿元。该股当日开盘10.32元,最高10.34元,最低10.18元,成交额达9886.39万元,换手率为2.31%。近日,千金药业发布公告称,公司下属子公司湖南千金湘江药业股份有限公司收到国家药品监督管理局核准签发的盐酸鲁拉西酮片《药品注册证书》,注册分类为化学药品4类,视同通过一致性评价。该药品用于治疗精神分裂症,截至目前累计研发投入为632.94万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200041885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600479","BK0186","BK0239"],"gpt_icon":0},{"id":"2590743955","title":"千金药业(600479.SH):盐酸鲁拉西酮片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590743955","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590743955?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:59","pubTimestamp":1765529985,"startTime":"0","endTime":"0","summary":"智通财经APP讯,千金药业(600479.SH)发布公告,近日,公司下属子公司湖南千金湘江药业股份有限公司(以下简称“千金湘江药业”)收到国家药品监督管理局核准签发的盐酸鲁拉西酮片的《药品注册证书》。盐酸鲁拉西酮片用于治疗精神分裂症,最早由Sunovion Pharmaceuticals Inc. 研发,于2010年10月在美国上市,于2019年1月国内批准进口。目前国内获得该药品注册证书的企业有江苏豪森药业集团有限公司、正大天晴药业集团股份有限公司、浙江海正药业股份有限公司等。据摩熵医药数据查询,盐酸鲁拉西酮片2025 年上半年国内市场销售金额约0.52亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0186","600479","BK0239"],"gpt_icon":0},{"id":"2590538059","title":"千金药业(600479)披露标的资产过渡期损益情况,12月10日股价下跌0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590538059","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590538059?lang=zh_cn&edition=full","pubTime":"2025-12-10 22:21","pubTimestamp":1765376492,"startTime":"0","endTime":"0","summary":"公告显示,本次交易涉及收购千金湘江药业28.92%股权和千金协力药业68.00%股权。评估基准日为2024年9月30日,千金湘江药业过渡期为2024年10月1日至2025年9月30日,千金协力药业过渡期为2024年10月1日至2025年10月31日。经天健会计师事务所审计,过渡期内千金湘江药业实现净利润135,203,152.10元,千金协力药业实现净利润35,252,082.95元,均未发生亏损,交易对方无需补偿,收益由千金药业享有。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000041967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","600479"],"gpt_icon":0},{"id":"2590538563","title":"千金药业:2025年三季度披露财务报表未将收购部分股权的利润纳入归母净利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2590538563","media":"证券日报 ","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590538563?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:42","pubTimestamp":1765374120,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月10日,千金药业在互动平台回答投资者提问时表示,公司2025年三季度披露财务报表未将收购部分股权的利润纳入归母净利润。两个标的收购股权的财务利润分别在2025年10月、2025年11月开始并表。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-10/doc-inhaiqhy9804634.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-10/doc-inhaiqhy9804634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600479"],"gpt_icon":0},{"id":"2585910544","title":"每周股票复盘:千金药业(600479)取消监事会并修订章程","url":"https://stock-news.laohu8.com/highlight/detail?id=2585910544","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585910544?lang=zh_cn&edition=full","pubTime":"2025-11-23 03:54","pubTimestamp":1763841252,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,千金药业报收于10.29元,较上周的11.07元下跌7.05%。公司公告汇总:千金药业2025年第三季度业绩说明会披露,卫生用品业务营收同比增长32%。公司公告汇总千金药业2025年第二次临时股东大会于2025年11月17日召开,审议通过关于取消监事会、变更注册资本并修订《公司章程》的议案,以及关于修订公司部分治理制度的议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600479","BK0186","BK0239"],"gpt_icon":0},{"id":"2584415838","title":"千金药业(600479)披露2025年第三季度业绩说明会召开情况,11月20日股价上涨0.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584415838","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584415838?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:35","pubTimestamp":1763649324,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘,千金药业报收于10.67元,较前一交易日上涨0.47%,最新总市值为52.52亿元。该股当日开盘10.67元,最高10.72元,最低10.6元,成交额达4210.09万元,换手率为0.94%。公司近日发布公告称,株洲千金药业股份有限公司于2025年11月20日召开2025年第三季度业绩说明会,公司董事长蹇顺、独立董事马理、董事会秘书朱溧、副总经理兼财务负责人彭意花出席。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000038483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","600479"],"gpt_icon":0},{"id":"2583565158","title":"每周股票复盘:千金药业(600479)拟取消监事会,注册资本变更至49221.0016万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583565158","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583565158?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:23","pubTimestamp":1763234591,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,千金药业报收于11.07元,较上周的10.79元上涨2.59%。本周关注点公司公告汇总:千金药业拟取消监事会,监事会职权由董事会审计委员会承接,股份总数变更为49221.0016万股。因回购注销限制性股票及发行股份购买资产,公司股份总数由42399.7117万股变更为49221.0016万股,注册资本相应变更。千金药业公告将于2025年11月20日15:00-16:00通过网络互动方式召开2025年第三季度业绩说明会,会议将在价值在线平台举行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600479","BK0186","BK0239"],"gpt_icon":0},{"id":"2583502385","title":"千金药业(600479)披露召开2025年第三季度业绩说明会,11月14日股价上涨0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502385","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583502385?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:33","pubTimestamp":1763130807,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,千金药业报收于11.07元,较前一交易日上涨0.91%,最新总市值为54.49亿元。该股当日开盘10.95元,最高11.14元,最低10.95元,成交额达1.09亿元,换手率为2.36%。公司近日发布公告称,株洲千金药业股份有限公司将于2025年11月20日15:00-16:00通过网络互动方式召开2025年第三季度业绩说明会,会议将在价值在线平台举行。公司董事长蹇顺、董事会秘书朱溧、财务负责人彭意花及独立董事马理将出席,就2025年第三季度报告相关内容与投资者交流。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400041919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","600479"],"gpt_icon":0},{"id":"2582608983","title":"千金药业(600479)披露拟取消监事会并修订公司章程,11月11日股价上涨1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582608983","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582608983?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:48","pubTimestamp":1762872504,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘,千金药业报收于10.94元,较前一交易日上涨1.11%,最新总市值为53.85亿元。该股当日开盘10.8元,最高10.94元,最低10.78元,成交额达7486.27万元,换手率为1.64%。近日,千金药业发布《2025年第二次临时股东大会会议材料》公告,宣布拟取消公司监事会,原监事会职权由董事会审计委员会承接。同时,因实施回购注销限制性股票及发行股份购买资产,公司股份总数由42399.7117万股变更为49221.0016万股,注册资本将相应变更。上述事项将提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100041279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","600479","BK0239"],"gpt_icon":0},{"id":"2580287403","title":"每周股票复盘:千金药业(600479)Q3净利增18.42%,股东户数降9.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580287403","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580287403?lang=zh_cn&edition=full","pubTime":"2025-11-02 09:53","pubTimestamp":1762048390,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,千金药业报收于10.63元,较上周的10.67元下跌0.37%。股本股东变化截至2025年9月30日,千金药业股东户数为3.68万户,较6月30日减少4023户,减幅9.85%。业绩披露要点2025年前三季度,千金药业主营收入27.18亿元,同比上升0.14%;归母净利润1.87亿元,同比上升11.47%;扣非净利润1.7亿元,同比上升4.74%。交易完成后,千金药业对千金湘江药业持股比例升至79.92%,对千金协力药业持股达100%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200002198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","600479"],"gpt_icon":0},{"id":"2579304905","title":"图解千金药业三季报:第三季度单季净利润同比增长18.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579304905","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579304905?lang=zh_cn&edition=full","pubTime":"2025-10-29 20:25","pubTimestamp":1761740757,"startTime":"0","endTime":"0","summary":"证券之星消息,千金药业2025年三季报显示,前三季度公司主营收入27.18亿元,同比上升0.14%;归母净利润1.87亿元,同比上升11.47%;扣非净利润1.7亿元,同比上升4.74%;其中2025年第三季度,公司单季度主营收入9.0亿元,同比上升13.91%;单季度归母净利润5963.0万元,同比上升18.42%;单季度扣非净利润5174.04万元,同比上升0.79%;负债率33.8%,投资收益4244.26万元,财务费用-1381.52万元,毛利率49.87%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900041585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600479"],"gpt_icon":0},{"id":"2575472006","title":"千金药业最新公告:子公司千金湘江药业获得富马酸伏诺拉生片与恩格列净片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2575472006","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575472006?lang=zh_cn&edition=full","pubTime":"2025-10-13 18:20","pubTimestamp":1760350808,"startTime":"0","endTime":"0","summary":"千金药业(600479.SH)公告称,公司下属子公司千金湘江药业近日收到国家药品监督管理局核准签发的富马酸伏诺拉生片(20mg、10mg)与恩格列净片(10mg、25mg)的《药品注册证书》。其中,富马酸伏诺拉生片适用于反流性食管炎,国内销售总额在2025年半年度为5.32亿元;恩格列净片是一种高选择性钠-葡萄糖协同转运蛋白2抑制剂,国内销售总额在2025年半年度为5.95亿元。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300021316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","600479"],"gpt_icon":0},{"id":"2570437894","title":"每周股票复盘:千金药业(600479)收购两子公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2570437894","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570437894?lang=zh_cn&edition=full","pubTime":"2025-09-28 03:59","pubTimestamp":1759003178,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘,千金药业报收于10.37元,较上周的10.53元下跌1.52%。本周,千金药业9月22日盘中最高价报10.57元。本周关注点来自公司公告汇总:千金药业拟发行股份及支付现金购买千金湘江药业28.92%股权和千金协力药业68.00%股权,合计作价62,346.69万元。标的公司采用收益法评估,千金湘江药业股东全部权益评估值为124,670.00万元,千金协力药业为38,671.00万元。交易完成后,上市公司对千金湘江药业持股比例将提升至79.92%,对千金协力药业实现100%控股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092800001001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600479","BK0186"],"gpt_icon":0},{"id":"2569455602","title":"每周股票复盘:千金药业(600479)完成收购两子公司股权过户","url":"https://stock-news.laohu8.com/highlight/detail?id=2569455602","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569455602?lang=zh_cn&edition=full","pubTime":"2025-09-21 02:59","pubTimestamp":1758394748,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘,千金药业报收于10.53元,较上周的10.96元下跌3.92%。本周关注点来自公司公告汇总:千金药业已合法取得千金湘江药业28.92%股权和千金协力药业68.00%股权,资产过户手续办理完毕。交易完成后,千金药业将持有千金湘江药业79.92%股权,千金协力药业将成为其全资子公司。标的资产已在核查意见出具日前完成过户至上市公司名下。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100000613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","600479"],"gpt_icon":0},{"id":"2568922564","title":"千金药业(600479)披露发行股份及支付现金购买资产之标的资产过户完成公告,9月17日股价下跌1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568922564","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568922564?lang=zh_cn&edition=full","pubTime":"2025-09-17 22:32","pubTimestamp":1758119544,"startTime":"0","endTime":"0","summary":"近日,千金药业发布关于发行股份及支付现金购买资产暨关联交易之标的资产过户情况的公告。公告显示,公司已于2025年9月12日收到中国证监会批复,同意其发行股份及支付现金购买资产的注册申请。截至公告披露日,本次交易涉及的标的资产过户手续已办理完毕。独立财务顾问和法律顾问均认为,本次交易实施过程合法合规,标的资产过户合法有效,后续事项的实施不存在实质性障碍。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700040511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0186","600479"],"gpt_icon":0},{"id":"2567136765","title":"每周股票复盘:千金药业(600479)并购获证监会注册批复","url":"https://stock-news.laohu8.com/highlight/detail?id=2567136765","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567136765?lang=zh_cn&edition=full","pubTime":"2025-09-14 05:20","pubTimestamp":1757798428,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘,千金药业报收于10.96元,较上周的10.92元上涨0.37%。本周关注点公司公告汇总:千金药业发行股份购买资产获证监会同意注册批复公司公告汇总:收购报告书持续督导期内收购人无重大调整计划公司公告汇总国泰海通证券股份有限公司作为财务顾问,对株洲千金药业股份有限公司收购报告书出具2025年半年度持续督导意见。截至2025年8月30日,交易已取得上交所审核通过,尚需中国证监会注册后办理过户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400001281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600479","BK0186"],"gpt_icon":0},{"id":"2566949709","title":"千金药业(600479)披露收购报告书半年度持续督导公告,9月11日股价上涨1.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566949709","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566949709?lang=zh_cn&edition=full","pubTime":"2025-09-11 22:28","pubTimestamp":1757600904,"startTime":"0","endTime":"0","summary":"截至2025年9月11日收盘,千金药业报收于11.23元,较前一交易日上涨1.45%,最新总市值为47亿元。该股当日开盘11.04元,最高11.23元,最低10.85元,成交额达1.42亿元,换手率为3.05%。近日,国泰海通证券股份有限公司发布了关于株洲千金药业股份有限公司收购报告书之2025年半年度持续督导意见。财务顾问认为,收购人及其一致行动人依法合规运作,持续督导期内未发生违反相关规定的行为。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091100038919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600479","BK0186","BK0239"],"gpt_icon":0},{"id":"2563880611","title":"千金药业(600479)2025年中报简析:净利润同比增长8.5%,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2563880611","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563880611?lang=zh_cn&edition=full","pubTime":"2025-08-31 06:05","pubTimestamp":1756591519,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期千金药业发布2025年中报。截至本报告期末,公司营业总收入18.18亿元,同比下降5.52%,归母净利润1.28亿元,同比上升8.5%。按单季度数据看,第二季度营业总收入8.13亿元,同比下降11.97%,第二季度归母净利润7456.98万元,同比上升4.26%。本报告期千金药业盈利能力上升,毛利率同比增幅10.63%,净利率同比增幅23.57%。去年的净利率为8.34%,算上全部成本后,公司产品或服务的附加值一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100001121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600479"],"gpt_icon":0},{"id":"2563047877","title":"图解千金药业中报:第二季度单季净利润同比增长4.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563047877","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563047877?lang=zh_cn&edition=full","pubTime":"2025-08-29 19:14","pubTimestamp":1756466092,"startTime":"0","endTime":"0","summary":"证券之星消息,千金药业2025年中报显示,公司主营收入18.18亿元,同比下降5.52%;归母净利润1.28亿元,同比上升8.5%;扣非净利润1.18亿元,同比上升6.58%;其中2025年第二季度,公司单季度主营收入8.13亿元,同比下降11.97%;单季度归母净利润7456.98万元,同比上升4.26%;单季度扣非净利润7013.62万元,同比上升4.5%;负债率33.63%,投资收益1880.36万元,财务费用-479.19万元,毛利率49.97%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900038165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600479"],"gpt_icon":0},{"id":"2563048757","title":"千金药业(600479)6月30日股东户数4.09万户,较上期减少4.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563048757","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563048757?lang=zh_cn&edition=full","pubTime":"2025-08-29 17:17","pubTimestamp":1756459046,"startTime":"0","endTime":"0","summary":"证券之星消息,近日千金药业披露,截至2025年6月30日公司股东户数为4.09万户,较3月31日减少1774.0户,减幅为4.16%。在中药行业个股中,千金药业股东户数低于行业平均水平,截至6月30日,中药行业平均股东户数为5.31万户。从股价来看,2025年3月31日至2025年6月30日,千金药业区间涨幅为2.36%,在此期间股东户数减少1774.0户,减幅为4.16%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900031978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600479","BK0186","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766085022884,"stockEarnings":[{"period":"1week","weight":0.0185},{"period":"1month","weight":-0.0315},{"period":"3month","weight":-0.0076},{"period":"6month","weight":0.0627},{"period":"1year","weight":-0.002},{"period":"ytd","weight":0.011}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0161},{"period":"3month","weight":0.0147},{"period":"6month","weight":0.1537},{"period":"1year","weight":0.1461},{"period":"ytd","weight":0.1565}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"株洲千金药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"36839人(较上一季度减少9.85%)","perCapita":"11360股","listingDate":"2004-03-12","address":"湖南省株洲市天元区株洲大道801号","registeredCapital":"49221万元","survey":" 株洲千金药业股份有限公司的主营业务是中成药、化学药、女性卫生用品的研发、生产和销售,以及药品的批发和零售业务。公司的主要产品是妇科千金片(胶囊)、补血益母丸(颗粒)、缬沙坦胶囊、马来酸依那普利片、盐酸地芬尼多片、水飞蓟宾葡甲胺片、苯磺酸氨氣地平片、非那雄胺片以及妇科专用棉巾系列等。公司连续十多年保持口服妇科炎症中成药市场第一品牌地位。“千金”是国家驰名商标。千金药业荣获“2025中国中药研发实力前50强”“2025大健康产业影响力品牌”等奖项。","listedPrice":23.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"千金药业(600479)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供千金药业(600479)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"千金药业,600479,千金药业股票,千金药业股票老虎,千金药业股票老虎国际,千金药业行情,千金药业股票行情,千金药业股价,千金药业股市,千金药业股票价格,千金药业股票交易,千金药业股票购买,千金药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"千金药业(600479)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供千金药业(600479)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}